Elekta loss widens in Q1 results

Radiation oncology firm Elekta posted a wider net loss in financial results for its first quarter (end-July 31).

For the quarter, net sales decreased 4% to 1.865 billion Swedish kronor ($261 million U.S.), compared with 1.912 billion kronor ($267.7 million U.S.) in the same period last year. The company attributed the decline to slower than expected growth in mature markets, especially in the U.S.

The company had a net loss of 137 million kronor ($19.2 million U.S.), compared with a net loss of 8 million kronor ($1.1 million U.S.) for the same quarter last year.

Page 1 of 1234
Next Page